Cytovia Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Cytovia Therapeutics's estimated annual revenue is currently $2.9M per year.
- Cytovia Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Cytovia Therapeutics has 38 Employees.
- Cytovia Therapeutics grew their employee count by -31% last year.
Cytovia Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder & CEO | Reveal Email/Phone |
2 | VP Finance Operations | Reveal Email/Phone |
3 | VP, General Counsel & Corporate Secretary | Reveal Email/Phone |
4 | VP, Finance & Administration | Reveal Email/Phone |
5 | Chief Operating Officer | Reveal Email/Phone |
6 | Senior Director, Preclinical Research | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Acting Chief Business Officer & Corporate Secretary | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Lab Manager | Reveal Email/Phone |
Cytovia Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Cytovia Therapeutics?
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.
keywords:N/A
N/A
Total Funding
38
Number of Employees
$2.9M
Revenue (est)
-31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cytovia Therapeutics News
Cytovia Therapeutics Reports Preclinical Activity of its iPSC-derived NK (iNK) Cells and Flex-NK Cell Engagers at the 2022 AACR Annual...
Cytovia CEO Daniel Teper/Courtesy Cytovia Therapeutics. Checkpoint inhibitors offer significant improvements in cancer care,...
Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.2M | 38 | 3% | N/A |
#2 | $5.9M | 38 | -25% | $2M |
#3 | N/A | 38 | 31% | N/A |
#4 | $4M | 38 | -19% | $26.2M |
#5 | $4M | 38 | -7% | $51.1M |